

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

Hep 3B2.1-7

RRID:CVCL_0326

Type: Cell Line

Proper Citation

RRID:CVCL_0326

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0326

Proper Citation: RRID:CVCL_0326

Description: Cell line Hep 3B2.1-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood hepatocellular carcinoma

Defining Citation: [PMID:233137](#), [PMID:2439335](#), [PMID:3023526](#), [PMID:3431441](#), [PMID:6248960](#), [PMID:6275024](#), [PMID:6288577](#), [PMID:7972006](#), [PMID:8050184](#), [PMID:8224613](#), [PMID:8389256](#), [PMID:8835345](#), [PMID:9290701](#), [PMID:9359923](#), [PMID:10523694](#), [PMID:11050057](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:20937217](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:24116068](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29610054](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32899426](#), [PMID:34320349](#), [PMID:35839778](#)

Comments: Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hep 3B2.1-7

Synonyms: Hep 3B2_1-7, Hep 3B 2.1-7, HEP3B217, Hep 3B2, HEP-3B2, HEP3B2, Hep-3B, HEP-3B, Hep 3B, Hep3B, HEP3B

Cross References: BTO:BTO_0000972, CLO:CLO_0003702, CLO:CLO_0003703, CLO:CLO_0003710, EFO:EFO_0002205, MCCL:MCC:0000221, CLDB:cl1627, CLDB:cl1628, CLDB:cl1629, CLDB:cl1630, AddexBio:C0015001/45, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HB-8064, BCRC:60434, BCRJ:0357, BioGRID_ORCS_Cell_line:810, BioSample:SAMN03473193, BioSample:SAMN10988098, cancercellines:CVCL_0326, CCRID:1101HUM-PUMC000376, CCRID:1101HUM-PUMC000474, CCRID:1102HUM-NIFDC00059, CCRID:3101HUMSCSP5045, CCRID:3101HUMTCHu106, CCRID:4201HUM-CCTCC00070, CCTCC:GDC0070, Cell_Model_Passport:SIDM00672, CGH-DB:454-3, CGH-DB:9069-4, ChEMBL-Cells:ChEMBL4106361, ChEMBL-Targets:ChEMBL4296437, CLS:305141, Cosmic:873401, Cosmic:928140, Cosmic:934549, Cosmic:948066, Cosmic:979729, Cosmic:999851, Cosmic:1019316, Cosmic:1177682, Cosmic:1351510, Cosmic:1518225, Cosmic:1628385, Cosmic:2023864, Cosmic:2162536, Cosmic:2301557, Cosmic:2321030, Cosmic:2668282, Cosmic:2773181, Cosmic:2816904, Cosmic-CLP:1240147, DepMap:ACH-000625, DSMZ:ACC-93, DSMZCellDive:ACC-93, ECACC:86062703, EGA:EGAS00001000978, GDSC:1240147, GEO:GSM207050, GEO:GSM501778, GEO:GSM565879, GEO:GSM887078, GEO:GSM888148, GEO:GSM936759, GEO:GSM1374531, GEO:GSM1669879, GEO:GSM2551564, Hysigen:TCH-C195, IARC_TP53:30036, IGRhCellID:Hep3B, IZSLER:BS TCL 78, KCB:KCB 200771YJ, KCB:KCB 200942YJ, KCLB:88064, LiGeA:CCLE_655, LIMORE:Hep3B, LINC_S_LDP:LCL-1924, Lonza:473, PharmacDB:Hep3B2_17_538_2019, PRIDE:PXD000533, PRIDE:PXD000535, PRIDE:PXD005291, PRIDE:PXD008190, PRIDE:PXD030304, Progenetix:CVCL_0326, PubChem_Cell_line:CVCL_0326, RCB:RCB2090, TKG:TKG 0291, TOKU-E:1439, TOKU-E:3574, Ubigen:YC-D002, Wikidata:Q54882746

ID: CVCL_0326

Record Creation Time: 20220427T220333+0000

Record Last Update: 20260920T003550+0000

Ratings and Alerts

No rating or validation information has been found for Hep 3B2.1-7.

Warning: Discontinued: RCB; RCB2090

Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4014 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Khanduja S, et al. (2026) Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. *Cell reports. Medicine*, 7(6), 102839.

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. *HGG advances*, 7(3), 100630.

Peng X, et al. (2026) Peroxisome-derived and liver-specific hydroxyacid oxidase 1-mediated hydrogen peroxide promotes ferroptosis by augmenting peroxisomal ROS. *Journal of advanced research*.

Xu M, et al. (2026) UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β -Catenin-Driven Hybrid EMT and NK Cell Evasion. *Cancer research*, 86(13), 3213.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Weiskirchen R, et al. (2026) Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review. *Medical sciences (Basel, Switzerland)*, 14(1).

Li Z, et al. (2026) Bio-inspired fractal-structured gel-drugs enable enhancing deep tumor penetration for efficient chemotherapy of hepatocellular carcinoma. *Journal of controlled release : official journal of the Controlled Release Society*, 394, 114899.

Wang LT, et al. (2026) ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer. *Experimental hematology & oncology*, 15(1).

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. *Cancer research communications*, 6(1), 178.

Li L, et al. (2026) USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation. *EMBO reports*, 27(9), 2406.

Xing J, et al. (2026) Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes. *Cell*, 189(9), 2556.

Guo WW, et al. (2026) CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. *International journal of biological sciences*, 22(7), 3389.

An X, et al. (2026) MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma. *Frontiers in immunology*, 17, 1849407.

Chen Z, et al. (2026) USP1 promotes hepatocellular carcinoma progression by modulating mitophagy via stabilizing MCM3 to regulate the Keap1-Nrf2 axis. *iScience*, 29(3), 114927.

Aita Y, et al. (2026) A functional SNP rs12718466 in APOA1 promoter modulates gene expression via interaction with SOX7. *The Journal of biological chemistry*, 302(6), 113101.

Luo Q, et al. (2026) ILF3 Regulates Cell Proliferation and Metastasis by Competitively Antagonizing the Interaction Between HMGCL and USP38 in Hepatocellular Carcinoma. *Human mutation*, 2026, 2654435.

Yu S, et al. (2026) Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. *Cancer research communications*, 6(5), 1109.

Lee J, et al. (2026) Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3 β /mTOR signaling in liver cancer. *Molecular oncology*, 20(6), 1591.

Lin Z, et al. (2026) Glypican-3-Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 550.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic/epigenetic axis. *Journal of translational medicine*, 24(1).